DTC Study Shows Limited Risk Statement Works, But Will Pharma Ad Practices Change?
Executive Summary
Viewers retain more risks and benefits in DTC ads showing only limited risk information, but experts predict it may not result in substantial change right away.
You may also be interested in...
TV Drug Ads: FDA May Pursue Further Research Before Policy Changes
US agency's study found that mentioning fewer risks in direct-to-consumer ads helped with recall and in some cases with recognition but led viewers to say they didn’t have enough information.
Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.
DTC Ad Risk Disclosures Could Be Limited To ‘Serious And Actionable’
Despite PhRMA’s concerns, FDA is proceeding with a study using modified versions of existing TV ads, but agency will revise study questions to focus on value of the ‘major statement’ and not other aspects of ads.